Mark Pearson
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Protein Degradation and Inhibitors, Biochemical and Molecular Research, Microtubule and mitosis dynamics, Lung Cancer Treatments and Mutations
Most-Cited Works
- → PML regulates p53 acetylation and premature senescence induced by oncogenic Ras(2000)827 cited
- → Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors(2004)610 cited
- → BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design(2019)560 cited
- → In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase(2004)536 cited
- → Transcriptional plasticity promotes primary and acquired resistance to BET inhibition(2015)518 cited
- → Drugging an undruggable pocket on KRAS(2019)420 cited
- → BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition(2020)393 cited
- → Health, Austerity and Economic Crisis(2014)273 cited
- → Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor(2016)221 cited
- → A Good Time for Making Work Pay? Taking Stock of In-Work Benefits and Related Measures across the OECD(2009)207 cited